EGFR signaling activation, such as gene amplification and somatic activating mutations (e.g., L858R and exon 19 deletions), is a major driver of non-small-cell lung cancer (NSCLC), which constitutes more than 85% of all lung cancer cases [3, 4]. This evidence concerns the gene EGFR and lung cancer.